News
Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...
Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...
"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive ...
Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...
In the world of consumer marketing, people-based data has become the gold standard. Demographics are just the starting point. Layered on top are deep behavioural insights into what people buy, browse, ...
The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...
Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...
NHS England has agreed a confidential deal with Orchard Therapeutics that will allow access to Libmeldy – a gene therapy for a rare childhood disease that is thought to be the most expensive ...
Pfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and business process, as part of a boardroom shake-up.
Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal.
Mallinckrodt has finally claimed FDA approval for terlipressin as a treatment for hepatorenal syndrome (HRS), after manufacturing problems scuppered an earlier attempt. Terlipressin – now given ...
It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, with no major safety issues reported after a year in patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results